Document:

SECURED PROMISSORY NOTE

 Exhibit 10.17 
 SECURED PROMISSORY NOTE 
  

			
	$10,000,000	 	Advance Date: March 20, 2007

 FOR VALUE RECEIVED, AEGERION PHARMACEUTICALS, INC., a Delaware corporation, for itself and each of
its Subsidiaries (the “Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc., a Maryland corporation or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Palo Alto, CA 94301 or
such other place of payment as the holder of this Secured Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of Ten Million Dollars
($10,000,000) together with interest at a floating rate equal to the prime rate as reported in the Wall Street Journal, and if not reported, then the prime rate next reported in the Wall Street Journal, plus two and one-half percentage points
(2.50%) per annum based upon a year consisting of 360 days, with interest computed daily based on the actual number of days in each month. 
 This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated March 20, 2007, by and between Borrower and Lender (as the same may from time to time be
amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is
made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined
herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. Reference to the Loan Agreement shall not affect or impair the absolute and unconditional obligation of the Borrowers to pay all principal
and interest and premium, if any, under this Promissory Note upon demand or as otherwise provided herein. 
 Borrower waives presentment and
demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or
defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California,
excluding any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction. 
  

					
	 BORROWER FOR ITSELF AND
 ON BEHALF OF ITS
SUBSIDIARIES:
	 	AEGERION PHARMACEUTICALS, INC.
			
		 	By:	 	 /s/ Gerald Wisler

		 	Title:	 	President and CEOWARRANT AGREEMENT

 Exhibit 10.18 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.

 WARRANT AGREEMENT 
 To Purchase
Shares of the Series A Preferred Stock of 
 Aegerion Pharmaceuticals, Inc. 
 Dated as of March 20, 2007 (the “Effective Date”) 
 WHEREAS,
Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has entered into a Senior Loan and Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology Growth Capital,
Inc., a Maryland corporation (the “Warrantholder”); 
 WHEREAS, the Company desires to grant to Warrantholder, in
consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of its Series A Preferred Stock pursuant to this Warrant Agreement (this “Agreement”); 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial accommodations
contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 
 1.
GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 
 For value received, the Company hereby grants to the Warrantholder, and the
Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time after the earliest to occur of (i) an Initial Public Offering (as defined below), (ii) a Private Offering (as defined below),
(iii) immediately prior to the consummation of a Merger Event (as defined below) or (iv) September 30, 2007, to subscribe for and purchase, from the Company, the number of fully paid and non-assessable shares of the Preferred Stock
(as defined below) determined as set forth below at the Exercise Price (as defined below) determined as set forth below. With respect to each Advance made under the Loan Agreement, the number of shares of Preferred Stock (“Shares”)
that may be purchased hereunder shall be equal to the quotient derived by dividing (i) 4.25% of such Advance by (ii) the applicable Exercise Price. The number and Exercise Price of such shares are subject to adjustment as provided in
Section 8. 
 As used herein, the following terms shall have the following meanings: 
 “Act” means the Securities Exchange Act of 1933, as amended. 
 “Charter” means the Company’s Certificate of Incorporation, as may be amended from time to time. 
 “Common Stock” means the Company’s common stock. 
 “Exercise Price” varies as to the date of the Advance on which the Shares to be purchased are based. With respect to Advances (including the initial Advance) made between the Effective Date and the
earliest to occur of (i) an Initial Public Offering, (ii) a Private Offering or (iii) September 30, 2007, the Exercise Price shall be the lower of 

 (A) $3.58 per share (as adjusted for stock splits, dividends, recapitalizations and similar events affecting the
Company’s Common Stock), and (B) (i) if the Company completes an Initial Public Offering prior to July 31, 2007, the Exercise Price with respect to any such Advances shall be equal to 85% of the price per share at which the
Company sold its stock to the public in the Initial Public Offering (i.e., before underwriter discounts and commissions) or (ii) if the Company completes a Private Offering prior to September 30, 2007, the Exercise Price with respect to
any such Advances shall be equal to 85% of the price per share at which the Company sold its equity securities in the Private Offering. With respect to Advances made after an Initial Public Offering occurring prior to July 31, 2007, the
Exercise Price will be equal to a price determined by the volume weighted average price of the Company’s Shares for a period of seven trading days before the date of such Advance. With respect to Advances made after a Private Offering occurring
prior to September 30, 2007, the Exercise Price shall be equal to the price per share at which the Company sold its equity securities in the Private Offering. In the event the Company does not complete an Initial Public Offering prior to
July 31, 2007 or a Private Offering prior to September 30, 2007, with respect to Advances made after September 30, 2007, the Exercise Price shall be $2.56995 [i.e., simple average of $3.58 and $1.8599] (in each case, as adjusted for
stock splits, dividends, recapitalizations and similar events affecting the Company’s Common Stock). 
 “Initial Public
Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a registration statement under the Act, which public offering has been declared effective by the Securities and Exchange Commission
(“SEC”); 
 “Merger Event” means a merger or consolidation involving the Company in which the Company is
not the surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock of another entity. 
 “Preferred Stock” means the Series A Preferred Stock of the Company and any other stock into or for which the Series A Preferred Stock
may be converted or exchanged, and upon and after the occurrence of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred Stock,
including, without limitation, the consummation of an Initial Public Offering of the Common Stock in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or retired,
“Preferred Stock” shall mean such Common Stock. 
 “Private Offering” means a sale or issuance by the Company
prior to an Initial Public Offering of equity securities in one private placement transaction or a series of related private placement transactions resulting in aggregate gross proceeds to the Company of at least $15,000,000. 
 “Purchase Price” means, with respect to any exercise of this Agreement, an amount equal to the applicable Exercise Price(s) as of the
relevant time multiplied by the number of shares of Preferred Stock requested to be purchased in respect of the applicable Advance(s) made under the Loan Agreement. 
 2. TERM OF THE AGREEMENT. 
 Except as otherwise provided for herein, the term of this Agreement and
the right to purchase Preferred Stock as granted herein (the “Warrant”) shall commence at any time after the earlier to occur of (i) an Initial Public Offering (as defined below), (ii) a Private Offering (as defined
below), (iii) immediately prior to the consummation of a Merger Event (as defined below) or (iv) September 30, 2007, and shall be exercisable for a period ending upon the earlier of (i) a Merger Event in which the consideration
consists entirely of cash and/or public securities that are freely tradable by the Warrantholder or (ii) the later to occur of (a) ten (10) years after the Effective Date or (b) five (5) years after the Initial Public
Offering. 
 3. EXERCISE OF THE PURCHASE RIGHTS. 
 (a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering
to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of
the Purchase Price in accordance with the terms set forth below, and in no event later than three (3)
  

 2 

 business days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of
Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases,
if any. 
 The Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of
all or a portion of the Warrant for shares of Preferred Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net
Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

					
		  		  	X = Y(A-B)
		  		  	   A

			
	Where:	  	      X =	  	the number of Shares to be issued to the Warrantholder.
			
		  	      Y =	  	the number of Shares requested to be exercised under this Agreement.
			
		  	      A =	  	the fair market value of one (1) Share at the time of issuance of such Shares.
			
		  	      B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Shares shall mean with respect
to each Share: 
 (i) if the exercise is in connection with an Initial Public Offering, and if the Company’s Registration
Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per Share shall be the initial “Price to Public” of the Common Stock specified in the final prospectus with respect to
the offering; 
 (ii) if the exercise is after, and not in connection with, an Initial Public Offering, and: 
 (1) if the Common Stock is traded on a securities exchange, the fair market value per Share shall be deemed to be the average of the closing
prices over a five (5) day period ending three days before the day the current fair market value of the securities is being determined; or 
 (2) if the Common Stock is actively traded over-the-counter, the fair market value per Share shall be deemed to be the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the ten
(10) day period ending three days before the day the current fair market value of the securities is being determined; 
 (iii) if
at any time the Common Stock is not listed on any securities exchange or quoted in The NASDAQ Stock Market or the over-the-counter market, the current fair market value per Share shall be determined in good faith by its Board of Directors, unless
the Company shall become subject to a Merger Event pursuant to which the Company is not the surviving party, in which case the fair market value per Share shall be deemed to be the per share value received by the holders of the Company’s
Preferred Stock on a common equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the
Company shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to
the Effective Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all
Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the 
  

 3 

 Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even
if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this
Agreement or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the Warrantholder is to receive by
reason of such automatic exercise. 
 4. RESERVATION OF SHARES. 
 During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights to purchase Preferred Stock
as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the Preferred Shares available hereunder. 
 5. NO FRACTIONAL SHARES OR SCRIP. 
 No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the applicable Exercise Price then in effect.

 6. NO RIGHTS AS SHAREHOLDER. 
 This
Agreement does not entitle the Warrantholder to any voting rights or other rights as a shareholder of the Company until this Agreement shall have been exercised and the shares purchasable upon such exercise shall have become deliverable, and then
only with respect to such shares. 
 7. WARRANTHOLDER REGISTRY. 
 The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s initial address, for purposes of such registry, is set forth below
Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such changed address to the Company. 
 8. ADJUSTMENT RIGHTS. 
 Each Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to
adjustment, as follows: 
 (a) Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful
provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of preferred stock or other securities or property of the successor corporation resulting from such
Merger Event that would have been issuable if Warrantholder had exercised this Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be
made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price and number
of shares of Preferred Stock purchasable) shall be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity
shall assume the obligations of this Agreement. 
 (b) Reclassification of Shares. Except as set forth in Section 8(a), if the
Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of
any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase
rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 
  

 4 

 (c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide
its Preferred Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Agreement shall be proportionately increased, or
(ii) in the case of a combination, the Exercise Price shall be proportionately increased, and the number of shares of Preferred Stock issuable upon the exercise of this Agreement shall be proportionately decreased. 
 (d) Stock Dividends. If the Company at any time while this Warrant is outstanding and unexpired shall: 
 (i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise Price shall be adjusted, from and after the
date of determination of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of
which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock outstanding immediately after
such dividend or distribution; or 
 (ii) make any other distribution with respect to Preferred Stock (or stock into which the
Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or
conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record date fixed for the determination of the
shareholders of the Company entitled to receive such distribution. 
 (e) Antidilution Rights. Additional antidilution rights
applicable to the Preferred Stock purchasable hereunder are as set forth in the Company’s Charter and shall be applicable with respect to the Preferred Stock issuable hereunder as if such Preferred Stock were issued and outstanding. The Company
shall promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter that materially affects the rights of the Preferred Stock. For the avoidance of doubt, there shall be no duplicate anti-dilution
adjustment pursuant to this Agreement and the Company’s Charter. To the extent of any such duplication or any conflict between this Section 8 and the Company’s Charter, the provisions of the Company’s Charter control. 

(f) Notice of Adjustments. Whenever an adjustment to the Exercise Price or the number of shares of Preferred Stock issuable upon exercise of
this Agreement is made pursuant to this Section 8, the Company shall send to the Warrantholder a notice setting forth, in reasonable detail, (i) the event requiring the adjustment, (ii) the amount of such adjustment, (iii) the
method by which such adjustment was calculated, (iv) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (v) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall cause
such notice to be mailed (by first class mail, postage prepaid, or by reputable overnight courier with all charges prepaid) within thirty (30) days of such adjustment addressed to the Warrantholder at the address for Warrantholder set forth in
the registry referred to in Section 7. 
 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 
 (a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly
reserved and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the
Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws and applicable agreements to which the Company or its security holders are parties. The Company has made
available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any
issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be
payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 
  

 5 

 (b) Due Authority. The execution and delivery by the Company of this Agreement and the performance
of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate
action on the part of the Company. This Agreement: (1) is not inconsistent with the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not
and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the
Company, enforceable in accordance with its respective terms (except as enforceability may be limited by applicable bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally and by general principles
of equity relating to enforceability). 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration
with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the
filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 
 (i) Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any other securities of the Company have been duly
authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in full compliance with all federal and state securities laws. 
 (d) Other Commitments to Register Securities. Except as set forth in this Agreement and that certain Investor Rights Agreement by and between the
Company and the parties named therein dated as of December 15, 2005 and except for an additional 4,140,000 shares of Common Stock outstanding, the Company is not, pursuant to the terms of any other agreement currently in existence, under any
obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (e) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Preferred Stock upon exercise of this Agreement, and the issuance of the Common Stock upon conversion
of the Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable
state securities laws. 
 (f) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock issuable upon the
exercise of this Agreement, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the Warrantholder, within
ten days after receipt of such request, a written statement confirming, if true, the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 
 10. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE WARRANTHOLDER. 
 This Agreement has been entered into by the Company in reliance upon the following representations, warranties and covenants of the Warrantholder: 
 (a) Investment Purpose. The right to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the Warrantholder’s rights
contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
  

 6 

 (b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon
exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements
thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 
 (c) Disposition of Warrantholder’s Rights. In no event will the Warrantholder make a disposition of any of its rights to acquire Preferred Stock or Preferred Stock issuable upon exercise of such rights unless and until
(i) it shall have notified the Company of the proposed disposition, and (ii) if requested by the Company, it shall have furnished the Company with an opinion of counsel (which counsel may either be inside or outside counsel to the
Warrantholder) satisfactory to the Company and its counsel to the effect that (A) appropriate action necessary for compliance with the Act has been taken, or (B) an exemption from the registration requirements of the Act is available.
Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of its rights to acquire Preferred Stock or Preferred Stock issuable on the exercise of such rights do not apply to transfers from the beneficial owner of any of
the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Preferred Stock when (1) such security shall have been effectively registered under the Act and sold by
the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the Act, or (3) a letter shall have been issued to the Warrantholder at its request by
the staff of the SEC or a ruling shall have been issued to the Warrantholder at its request by the SEC stating that no action shall be recommended by such staff or taken by the SEC, as the case may be, if such security is transferred without
registration under the Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall
terminate, as hereinabove provided, the Warrantholder or holder of a share of Preferred Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from the Company, without expense to such holder, one or more
new certificates for this Agreement or for such shares of Preferred Stock not bearing any restrictive legend. 
 (d) Financial Risk.
The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (e) Risk of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the
Securities Exchange Act of 1934, as amended (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Act is not in effect when it desires to
sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold such securities for an indefinite period. The Warrantholder
also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made only in accordance
with the terms and conditions of that Rule. 
 (f) Accredited Investor. Warrantholder is an “accredited investor” within the
meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (g) Diligence. Warrantholder has had an
opportunity to discuss the Company’s business, management and financial affairs with its management and an opportunity to review the Company’s facilities. 
 11. LEGEND. It is understood that this Warrant, all shares of Preferred Stock issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the Act
and any applicable state securities laws) may bear the following legend: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.” 
  

 7 

	12.	TRANSFERS. 

 Subject to the terms and conditions
contained in Section 10, this Agreement and all rights hereunder are transferable in whole or in part by the Warrantholder and any successor transferee, provided, that, prior to an Initial Public Offering, in no event shall the number of
transfers of the rights and interests in this Agreement exceed three (3) transfers. The transfer shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the
“Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. 
  

	13.	MISCELLANEOUS. 

 (a) Effective Date. The
provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company.

 (b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either
by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and
where damages will not be readily ascertainable. 
 (c) No Impairment of Rights. The Company will not, by amendment of its Charter or
through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 
 (d) Severability. In the event any
one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by
a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (e) Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other
communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of:
(i) the first business day after transmission by facsimile or hand delivery or deposit with an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with
proper first class postage prepaid (provided, that any Advance Request shall not be deemed received until Lender’s actual receipt thereof), and shall be addressed to the party to be notified as follows: 
 If to Warrantholder: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 
 Legal Department 
 Attention: Chief Legal Officer 
 400 Hamilton Avenue 
 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
  

 8 

 With a copy to: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 
 Attention: Bryan Jadot and Parag Shah 
 2 Oliver Street, Suite 611 
 Boston, MA 02109 
 Facsimile: 617-330-9131 
 Telephone: 617-261-6552 
 If to the Company: 
 Aegerion Pharmaceuticals, Inc. 
 Attention: William Lewis, Chief Financial Officer 
 1140 Route 22 East, Suite 304 
 Bridgewater, NJ 08807 
 Facsimile: 908-541-1155 
 Telephone: 908-704-1300 
 With a copy to: 
 GOODWIN PROCTER LLP 
 Attention: Mark D. Smith, Esq. 
 53 State Street 
 Boston, MA 02109 
 Facsimile: 617-523-1231 
 Telephone: 617-570-1750 
 or to such other address as each party may designate for itself by like notice. A
notice delivered to the Company or Warrantholder shall be valid despite the failure to deliver a copy of such notice to any other person. 
 (f) Entire Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term
sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto.

 (g) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof. 
 (h) Advice of Counsel. Each of the parties represents to each other
party hereto that it has discussed (or had an opportunity to discuss) with its counsel this Agreement and, specifically, the provisions of Sections 13(n), 13(o) and 13(p). 
 (i) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an
ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement. 
 (j) No Waiver. No omission or delay by Warrantholder at any time to enforce any right or
remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in any way
affect the right of Warrantholder to enforce such provisions thereafter. 
 (k) Survival. All agreements, representations and
warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder or the Company, as applicable, and shall survive the execution and delivery of this Agreement and the expiration or other
termination of this Agreement. 
  

 9 

 (l) Governing Law. This Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 (m) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution
and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b) waives any objection as to jurisdiction or venue in Santa Clara County,
California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process
on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 13(g), and shall be deemed effective and received as set forth in
Section 13(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 (n) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically
resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE
COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY
AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way
connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. If this jury waiver is for any
reason unenforceable, all disputes shall be resolved by binding arbitration conducted under the commercial arbitration rules of the American Arbitration Association in Palo Alto, California. 
 (o) Specific Performance. Warrantholder and Company agree that either may be irreparably damaged by any breach or threatened breach of this
Agreement. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Agreement by Warrantholder or Company, the other party shall, in addition to all other remedies, be entitled to seek a temporary or permanent injunction
and/or a decree for specific performance, in accordance with the provisions hereof. Warrantholder and Company each waives the claim or defense that it has an adequate remedy at law, and such person shall not offer in any such action or proceeding
the claim or defense that such remedy at law exists. 
 (p) Counterparts. This Agreement and any amendments, waivers, consents or
supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the
same instrument. 
 [Remainder of Page Intentionally Left Blank] 
  

 10 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers
thereunto duly authorized as of the Effective Date. 
  

					
	 COMPANY:
	 	AEGERION PHARMACEUTICALS, INC.
			
		 	By:	 	 /s/ Gerald Wisler

		 	Title:	 	President and Chief Executive Officer

  

					
	 WARRANTHOLDER:
	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
			
		 	By:	 	 /s/ Scott Harvey

		 	Title:	 	Chief Legal Officer

  

 11 

 EXHIBIT I 
 NOTICE OF EXERCISE 
 To: Aegerion Pharmaceuticals, Inc. 
  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series A Preferred Stock of
Aegerion Pharmaceuticals, Inc., pursuant to the terms of the Agreement dated the          day of March 2007 (the “Agreement”) between Aegerion Pharmaceuticals, Inc. and the Warrantholder, and
[CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	In exercising its rights to purchase the Series A Preferred Stock of Aegerion Pharmaceuticals, Inc., the undersigned hereby confirms and acknowledges the investment representations
and warranties made in Section 10 of the Agreement. 

  

	(3)	Please issue a certificate or certificates representing said shares of Series A Preferred Stock in the name of the undersigned or in such other name as is specified below.

  

	
	  

	(Name)
	
	  

	(Address)

 WARRANTHOLDER:    HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

 

			
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

  

 12 

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 
 The undersigned Aegerion Pharmaceuticals, Inc., hereby acknowledge receipt of the “Notice
of Exercise” from Hercules Technology Growth Capital, Inc., to purchase [            ] shares of the Series A Preferred Stock of Aegerion Pharmaceuticals, Inc., pursuant to the
terms of the Agreement, and further acknowledges that [            ] shares remain subject to purchase under the terms of the Agreement. 
  

					
	 COMPANY:
	 	AEGERION PHARMACEUTICALS, INC.
			
		 	By:	 	  

			
		 	Title:	 	  

			
		 	Date:	 	  

  

 13 

 EXHIBIT III 
 TRANSFER NOTICE 
 (To transfer or assign the foregoing Agreement execute this form and supply required information. Do not
use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are
hereby transferred and assigned to 
  

											
	  
	 	 	 	 
	(Please Print)	 	 	 	 	 	 

											
				
	whose address is	 	  
	 	 	 	 

											
			
	  
	 	 	 	 
					
	 	 	Dated:	 	  
	 	 	 	 
					
	 	 	Holder’s Signature:	 	  
	 	 	 	 
					
	 	 	Holder’s Address:	 	  
	 	 	 	 
				
	 	 	  
	 	 	 	 
				
	Signature Guaranteed:	 	  
	 	 	 	 

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the
Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 
  

 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]